Media headlines about Viewray (NASDAQ:VRAY) have trended somewhat negative recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Viewray earned a news impact score of -0.05 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.5832711144007 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
NASDAQ:VRAY traded down $0.19 during trading hours on Friday, hitting $6.35. 347,139 shares of the company traded hands, compared to its average volume of 642,944. The stock has a market cap of $469.21, a P/E ratio of -6.11 and a beta of 0.63. Viewray has a twelve month low of $4.40 and a twelve month high of $10.64. The company has a debt-to-equity ratio of 22.47, a current ratio of 2.18 and a quick ratio of 1.84.
Viewray (NASDAQ:VRAY) last released its earnings results on Monday, March 12th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.13). The company had revenue of $19.90 million for the quarter, compared to analysts’ expectations of $21.23 million. The firm’s revenue was up 23.6% compared to the same quarter last year. equities research analysts anticipate that Viewray will post -0.71 EPS for the current year.
VRAY has been the subject of a number of analyst reports. BidaskClub upgraded shares of Viewray from a “hold” rating to a “buy” rating in a research note on Friday, December 22nd. Mizuho reiterated a “buy” rating and set a $12.00 target price on shares of Viewray in a research note on Tuesday, January 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Viewray in a research note on Friday, January 5th. Finally, B. Riley initiated coverage on shares of Viewray in a research note on Thursday, February 8th. They set a “buy” rating and a $13.50 target price for the company. Two analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $11.58.
In related news, insider James F. Dempsey sold 75,243 shares of the company’s stock in a transaction on Wednesday, March 14th. The shares were sold at an average price of $7.57, for a total transaction of $569,589.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 62.81% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Viewray (VRAY) Receiving Somewhat Negative Media Coverage, Study Shows” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/07/viewray-vray-receiving-somewhat-negative-media-coverage-study-shows.html.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.